| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Stephen Vickery | Q59166446 |
| P2093 | author name string | Jacqueline L Olin | |
| Lisa S Smith | |||
| Olga M Klibanov | |||
| Shannon H Williams | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro | Q27472610 | ||
| Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease | Q27473126 | ||
| SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells | Q27473129 | ||
| Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease | Q27485288 | ||
| Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients | Q27487949 | ||
| Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha | Q27645411 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Replication of hepatitis C virus | Q27860957 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | Q28274666 | ||
| Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons | Q28274676 | ||
| Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial | Q28298301 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites | Q34323105 | ||
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
| Pharmacokinetics of peginterferons | Q35204875 | ||
| The hepatitis C virus life cycle as a target for new antiviral therapies | Q36813367 | ||
| Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. | Q37772959 | ||
| New direct-acting antivirals in the development for hepatitis C virus infection | Q37823323 | ||
| Hepatitis C and progression of HIV disease | Q39607141 | ||
| Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro | Q40882812 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients | Q42978510 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. | Q42994273 | ||
| The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group | Q43000743 | ||
| Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. | Q43001141 | ||
| Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 | ||
| Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin | Q43032187 | ||
| Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group | Q43036483 | ||
| Hepatitis C Virus Infection in Patients Infected with the Human Immunodeficiency Virus | Q43039164 | ||
| Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir | Q43039208 | ||
| Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. | Q43040809 | ||
| Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy | Q43041935 | ||
| Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients | Q45741644 | ||
| Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. | Q45788301 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 951-974 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C | |
| P478 | volume | 31 |
| Q34709772 | In Silico screening on the three-dimensional model of the Plasmodium vivax SUB1 protease leads to the validation of a novel anti-parasite compound |
| Q37699271 | MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo |
| Q38095820 | Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions |
Search more.